Integra Lifesciences Holdings Corp (IART) Given Average Rating of “Buy” by Analysts

Integra Lifesciences Holdings Corp (IART) Given Average Rating of “Buy” by Analysts

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) have been given a consensus rating of “Buy” by the eleven research firms that are presently covering the firm. Three investment analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $48.21.

A number of research firms have weighed in on IART. Jefferies Group LLC boosted their target price on shares of Integra Lifesciences Holdings Corp from $50.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Royal Bank of Canada reissued a “sector perform” rating and set a $48.00 target price (up previously from $46.00) on shares of Integra Lifesciences Holdings Corp in a research report on Tuesday. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Integra Lifesciences Holdings Corp in a research report on Wednesday, January 11th. Zacks Investment Research lowered shares of Integra Lifesciences Holdings Corp from a “buy” rating to a “hold” rating in a research report on Friday, January 6th. Finally, Barclays PLC reissued an “equal weight” rating and set a $42.00 target price (down previously from $84.00) on shares of Integra Lifesciences Holdings Corp in a research report on Friday, January 13th.

In other news, Director James M. Sullivan sold 15,658 shares of the company’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $45.89, for a total transaction of $718,545.62. Following the completion of the transaction, the director now owns 70,154 shares of the company’s stock, valued at $3,219,367.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Glenn Coleman sold 13,865 shares of the company’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $45.91, for a total transaction of $636,542.15. Following the transaction, the vice president now directly owns 18,519 shares of the company’s stock, valued at approximately $850,207.29. The disclosure for this sale can be found here. 21.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Sectoral Asset Management Inc raised its position in shares of Integra Lifesciences Holdings Corp by 14.3% in the third quarter. Sectoral Asset Management Inc now owns 69,200 shares of the life sciences company’s stock worth $5,712,000 after buying an additional 8,640 shares in the last quarter. American International Group Inc. raised its position in shares of Integra Lifesciences Holdings Corp by 0.6% in the third quarter. American International Group Inc. now owns 22,423 shares of the life sciences company’s stock worth $1,851,000 after buying an additional 129 shares in the last quarter. Americafirst Capital Management LLC bought a new position in shares of Integra Lifesciences Holdings Corp during the third quarter worth approximately $1,638,000. Pacer Advisors Inc. bought a new position in shares of Integra Lifesciences Holdings Corp during the third quarter worth approximately $194,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Integra Lifesciences Holdings Corp during the fourth quarter worth approximately $12,288,000. 44.37% of the stock is owned by institutional investors and hedge funds.

Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up 0.61% on Monday, reaching $46.25. The company’s stock had a trading volume of 592,205 shares. The company has a market capitalization of $3.50 billion, a price-to-earnings ratio of 55.06 and a beta of 0.80. The stock has a 50 day moving average price of $42.96 and a 200-day moving average price of $57.56. Integra Lifesciences Holdings Corp has a 1-year low of $40.51 and a 1-year high of $88.86.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last released its earnings results on Wednesday, April 26th. The life sciences company reported $0.39 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.40 by $0.01. The firm had revenue of $258.60 million for the quarter, compared to analyst estimates of $254.19 million. Integra Lifesciences Holdings Corp had a return on equity of 16.11% and a net margin of 6.09%. The firm’s revenue was up 9.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.38 EPS. Equities analysts predict that Integra Lifesciences Holdings Corp will post $1.92 earnings per share for the current fiscal year.

About Integra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Related posts

Leave a Comment